<DOC>
	<DOCNO>NCT02832128</DOCNO>
	<brief_summary>The objective pilot study explore whether repeat dos AUT00063 provide indication improvement performance test across battery speech hear assessment cochlear implant user .</brief_summary>
	<brief_title>Evaluating Possible Improvement Speech Hearing Tests After 28 Days Dosing Study Drug AUT00063 Compared Placebo ( QuicKfire )</brief_title>
	<detailed_description>Reduced activity certain site brain call `` voltage-gated potassium channel '' , link hearing problem . The study drug , AUT00063 , develop help improve recognition speech aim improve action voltage-gated potassium channel hear pathway brain help treat hearing problem . The main purpose study find whether AUT00063 improve understand speech 28 day treatment compare placebo ( dummy drug contain study drug ) patient receive cochlear implant ( CI ) post-lingual deafness . Efficacy investigate number assessment include speech recognition testing , parameter central auditory processing measure use test involve direct stimulation via CI , questionnaires . Safety assessment also conduct throughout study include physical examination , ECGs blood sampling . It plan 20 people receive cochlear implant within last 9 36 month take part study . The people recruit around 4 hospital site UK .</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<criteria>Male female age â‰¥ 18 year . Native English speaking . Received unilateral cochlear implant within last 9 48 month postlingual deafness . Less optimal speech perception time enrolment ( define score 25 % 95 % BamfordKowalBench ( BKB ) sentence . Fully train optimised time enrolment . CI device work satisfactorily intervention 4 week prior first dose study medication . Signed date informed consent . Not able understand comply requirement study . CI undertaken primarily management severe tinnitus . Moderate severe depression generalise anxiety . Currently take plan take medication prohibit study protocol . History important cardiac , endocrine , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic , major disease deem clinically significant . Clinically significant ECG abnormality prolong QT interval . Screening laboratory safety test result outside normal range deem clinically significant investigator . Any acute disabling illness . Clinically significant alcohol drug abuse . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives investigational drug . For woman : Pregnant nursing . For men woman : Not willing able use adequate method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cochlear Implant</keyword>
</DOC>